GBS Sero-correlate of Protection

NCT02215226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35274

Last updated 2018-09-13

No results posted yet for this study

Summary

Compare anticapsular antibody levels against Group B Streptococcus at delivery in mothers and their infants who develop disease versus those who do not. Use this comparison to establish antibody levels associated with reductions in risk of GBS disease in infants aged less than 90 days.

Conditions

  • Invasive Group B Streptococcus Disease

Sponsors & Collaborators

  • Novartis Vaccines

    collaborator INDUSTRY
  • University of Witwatersrand, South Africa

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-12-09
Completion
2016-12-31

Countries

  • South Africa

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02215226 on ClinicalTrials.gov